GlassScriptPhysician profile
John A Cochrane
NPI 1124551775
$4,665.29
in general payments reported to CMS, 2019-2025
33 companies · $1,046 in 2025
The $1,046 reported for 2025 was more than what a typical Urology provider received nationally (typical 2025 total: $631).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $226 · 2020: $92.69 · 2021: $236 · 2022: $1,030 · 2023: $1,202 · 2024: $832 · 2025: $1,046.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,045 · Education: $35.06.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,045.30 |
| Education | $35.06 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic, INC. | $1,279.27 | 2022-2025 | Interstim, Altaviva |
| Axonics, INC. | $535.25 | 2020-2024 | Bulkamid, Axonics |
| Boston Scientific Corporation | $487.61 | 2019-2025 | Axonics, Spaceoar Vue System - 10ml |
| Olympus America INC. | $296.88 | 2022-2025 | Itind System |
| Coloplast Corp | $209.26 | 2022-2025 | |
| Urogen Pharma, INC. | $175.94 | 2023-2025 | Jelmyto |
| Antares Pharma, INC. | $161.29 | 2022-2025 | Xyosted, Tlando, Nocdurna |
| Calyxo, INC. | $156.16 | 2025 | Cvac Aspiration System |
| Dendreon Pharmaceuticals LLC | $146.91 | 2024 | Provenge |
| Ferring Pharmaceuticals INC. | $145.04 | 2024-2025 | Adstiladrin |
| Astellas Pharma US INC | $139.03 | 2022-2024 | Myrbetriq, Xtandi |
| Myriad Genetic Laboratories, INC. | $95.27 | 2023-2025 | Prolaris, Myrisk |
| Sumitomo Pharma America, INC. | $93.72 | 2023-2024 | Orgovyx, Gemtesa |
| Uroviu Corporation | $80.43 | 2022 | |
| Teleflex LLC | $59.65 | 2023-2025 | Urolift, Barrigel |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Procept Biorobotics Corporation | $53.98 | 2023-2024 | Aquabeam Robotic System, Aquabeam System |
| Janssen Biotech, INC. | $50.35 | 2025 | Erleada |
| C. R. Bard, INC. & Subsidiaries | $49.48 | 2025 | Personal Catheter Intermittent Catheter |
| Shionogi INC | $43.71 | 2024-2025 | Fetroja |
| Abbvie INC. | $43.65 | 2022-2024 | |
| Merck Sharp & Dohme LLC | $42.71 | 2024 | Lynparza |
| Bioprotect Medical, INC. | $41.92 | 2025 | Bioprotect Balloon Implant System |
| Halozyme INC | $40.75 | 2023 | |
| Astrazeneca Pharmaceuticals LP | $35.06 | 2025 | Imfinzi |
| Dentsply Ih Ab | $32.42 | 2023 | Lofric |
| Pfizer INC. | $30.64 | 2022 | |
| Valencia Technologies Corporation | $25.76 | 2025 | Ecoin Device Kit |
| 180 Medical, INC. | $21.62 | 2025 | |
| Endo USA, INC. | $21.20 | 2025 | Xiaflex |
| Photocure INC | $20.00 | 2023 | Cysview |
| Intercept Pharmaceuticals, INC. | $19.57 | 2023 | Ocaliva |
| Avation Medical, INC. | $15.85 | 2025 | Vivally System |
| Tolmar Pharmaceuticals, INC. | $14.91 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Cochrane listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.